EACS2023: 667 Delay between primary care access and antiretroviral therapy initiation in the most precarious people living with HIV in Northern France: a monocentric study A. Diarra , A. Meybeck , M. Tétart , S. Pretre , B. Fragale , E.K. Alidjinou , L. Bocket , F. Ajana , O. Robineau Hôpital Gustave Dron, Department of Infectious Diseases, Tourcoing, France, CHU Lille, Virology Laboratory ULR 3610, Lille, France, Médecin Solidarité Lille, Lille, France General data Abstract category: Access and delivery of care Abstract body Purpose: In French Hospitals, permanent access to healthcare (PASS) units offer permanent and free healthcare to precarious populations with no health insurance coverage. PASS units provide freely some treatments, but not HIV antiretroviral therapy (ART) in our center. Our study aims to assess the delay between the initial PASS HIV consultation and ART initiation. Method: We conducted a monocentric retrospective study in our regional referral center in Northern France, with more than 2000 people living with HIV (PLHIV) currently under follow-up. All PLHIV who were tested in the PASS from 2014 to 2022 were included. Demographic and immuno-virological characteristics and therapeutic data were recorded. Results: A total of 63 PLHIV, were included. Among them, 59% (37/63) were women and 65% (40/63) were from Sub-Saharan African countries. Most patients identified as heterosexual (34/54, 63%). The median age was 31 years (Interquartile range IQR: 16). Median delay between the first PASS consultation and ART initiation was 12 days (IQR: 48), with a delay significantly shorter in ART experimented patients as compared to naïve patients (0 vs 24days, p = 0.01). After 6 months of follow-up, 58% (25/43) of patients reached undetectable viral load vs 18% (8/45) initially ( p < 0.0001). At 12 months, an undetectable viral load was achieved for 79% (26/33) of PLHIV. Protease inhibitors and integrase strand transfer inhibitors were mostly prescribed (29% [18/63] and 57% [36/63] respectively). Conclusions: Despite the lack of PASS funding for ART, initiation of ART was early, mainly using drugs returned by PLHIV on regular follow-ups who changed ART. This care led to HIV RNA undetectability for most patients. Fundings of ART in the most precarious PLHIV who benefit from PASS are urgently needed in Northern France. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 2 2 1,3 1 1 2 3 33
RkJQdWJsaXNoZXIy Mzc2ODc=